These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 38937399)
21. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J; Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032 [TBL] [Abstract][Full Text] [Related]
22. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction. Hadden RD; Marreno F Ther Adv Neurol Disord; 2015 Jan; 8(1):14-9. PubMed ID: 25584070 [TBL] [Abstract][Full Text] [Related]
24. IgPro20, the Polyneuropathy and Treatment with Hizentra Berger M; Harbo T; Cornblath DR; Mielke O Immunotherapy; 2018 Aug; 10(11):919-933. PubMed ID: 29764262 [TBL] [Abstract][Full Text] [Related]
25. Retrospective correlation analysis of plasma Immunoglobulin G and clinical performance in CIDP. Markvardsen LK; Bruun-Sørensen S; Christiansen I; Andersen H PeerJ; 2019; 7():e6969. PubMed ID: 31143558 [TBL] [Abstract][Full Text] [Related]
26. A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States. Mallick R; Carlton R; Van Stiphout J Pharmacoecon Open; 2023 Mar; 7(2):243-255. PubMed ID: 36757567 [TBL] [Abstract][Full Text] [Related]
27. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749 [TBL] [Abstract][Full Text] [Related]
28. Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Merkies ISJ; van Schaik IN; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; J Peripher Nerv Syst; 2022 Jun; 27(2):159-165. PubMed ID: 35266243 [TBL] [Abstract][Full Text] [Related]
29. Changes in axonal and clinical function during intravenous and subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Hansen PN; Mohammed AA; Markvardsen LK; Andersen H; Tankisi H; Sindrup SH; Krøigård T J Peripher Nerv Syst; 2023 Sep; 28(3):425-435. PubMed ID: 37212187 [TBL] [Abstract][Full Text] [Related]
30. Chronic inflammatory demyelinating polyneuropathy and HEV antibody status: A case-control study from Lazio, Italy. Moret F; Spada E; Ceccanti M; Libonati L; D'Andrea E; Villano U; Madonna E; Chionne P; Carocci A; Pisani G; Fionda L; Antonini G; Petrucci A; Bruni R; Ciccaglione AR; Taliani G; Rivano Capparuccia M; Nobile-Orazio E; Inghilleri M; Cambieri C J Neurol Sci; 2024 Apr; 459():122959. PubMed ID: 38490091 [TBL] [Abstract][Full Text] [Related]
31. Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. Cianci P; Salvatore S; Moretti A; Berardinelli A; Salvatoni A; Marinoni M; Agosti M J Pediatr Neurosci; 2019; 14(1):38-41. PubMed ID: 31316642 [TBL] [Abstract][Full Text] [Related]
36. Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Alcantara M; Hartung HP; Lawo JP; Durn BL; Mielke O; Bril V Clin Neurophysiol; 2021 Sep; 132(9):2184-2190. PubMed ID: 34293528 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases. Sala TP; Crave JC; Duracinsky M; Lepira Bompeka F; Tadmouri A; Chassany O; Cherin P Autoimmun Rev; 2018 Sep; 17(9):873-881. PubMed ID: 30005853 [TBL] [Abstract][Full Text] [Related]
38. Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy. Alsolaihim A; Baker SK Case Rep Neurol; 2020; 12(1):73-77. PubMed ID: 32231547 [TBL] [Abstract][Full Text] [Related]
39. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. Abolhassani H; Sadaghiani MS; Aghamohammadi A; Ochs HD; Rezaei N J Clin Immunol; 2012 Dec; 32(6):1180-92. PubMed ID: 22730009 [TBL] [Abstract][Full Text] [Related]